Table 2.

Cytokine and cytokine receptor SNPs and risk of NSCLC by race

CytokineSNP identifierCaucasians
African-Americans
OR* (95% CI)PPOR* (95% CI)PP
Proinflammatory cytokines and cytokine receptors
IL1Ars17561Ala114Ser0.79 (0.54-1.14)0.630.271.54 (0.69-3.45)0.870.37
IL1Ars2071374IVS4-109 A/C1.05 (0.72-1.51)0.890.82 (0.40-1.67)0.94
IL1Brs1071676Ex7-97 G/C0.88 (0.60-1.28)0.740.270.79 (0.34-1.83)0.940.37
IL1Brs1143634Phe105Phe0.87 (0.59-1.26)0.720.72 (0.30-1.76)0.94
IL1Brs3136558IVS3-123 A/G0.93 (0.64-1.36)0.870.99 (0.43-2.25)0.99
IL1Brs1143627A-31G1.23 (0.85-1.78)0.631.29 (0.48-3.52)0.94
IL1Brs16944G-511A1.23 (0.84-1.78)0.630.77 (0.31-1.91)0.94
IL2rs2069763Leu38Leu0.95 (0.66-1.38)0.890.290.88 (0.39-2.00)0.980.76
IL2rs2069762A-330C1.38 (0.74-2.56)0.641.23 (0.07-22.11)0.98
IL6rs1800797G-597A1.25 (0.85-1.83)0.630.273.06 (1.04-9.02)0.430.13
IL6rs1800795C-174G1.32 (0.90-1.94)0.613.74 (1.26-11.10)0.24
IL6Rrs8192284Asp358Ala1.17 (0.80-1.71)0.720.88 (0.40-1.96)0.98
IL7Rrs1494555Ile138Val1.65 (1.14-2.39)0.540.0020.56 (0.25-1.23)0.740.04
IL7Rrs7737000His165His1.60 (1.05-2.45)0.564.24 (1.61-11.17)0.24
IL8rs4073A-251T1.24 (0.82-1.88)0.630.270.24 (0.03-1.74)0.740.30
IL8rs2227306IVS1+298 G/A1.31 (0.88-1.94)0.610.83 (0.37-1.86)0.94
IL8RArs28543861379bp 3′ STP G/C0.79 (0.44-1.42)0.721.10 (0.53-2.29)0.98
IL12Ars582537IVS2-701 C/A1.08 (0.72-1.62)0.860.86 (0.42-1.79)0.98
IL12Brs3212227Ex8+159 A/C0.74 (0.51-1.08)0.611.86 (0.86-4.00)0.73
IL15rs1493013Ex3+163 A/G1.11 (0.74-1.67)0.830.271.06 (0.50-2.22)0.980.04
IL15rs2254514Ex3-92 G/A1.09 (0.76-1.57)0.860.97 (0.44-2.13)0.98
IL15rs2857261IVS3+8 A/G1.22 (0.82-1.83)0.662.91 (1.22-6.96)0.24
IL15rs1057972Ex9-181 T/A1.18 (0.79-1.76)0.723.99 (1.32-12.08)0.24
IL15rs10833Ex9-66 G/A1.09 (0.74-1.58)0.861.16 (0.52-2.60)0.98
IL15RArs2296135Ex8-361 C/A1.37 (0.90-2.10)0.610.271.21 (0.58-2.55)0.940.30
IL15RArs2296141IVS6-242 G/A0.81 (0.49-1.34)0.721.70 (0.73-3.96)0.83
IL15RArs2228059Asn146Thr1.18 (0.77-1.83)0.721.57 (0.76-3.27)0.83
IL15RArs3136614IVS4+32 A/G1.05 (0.72-1.52)0.891.27 (0.54-3.01)0.94
IFNAR2rs3153IVS1-4640 G/A1.23 (0.85-1.78)0.630.271.65 (0.73-3.71)0.830.33
IFNAR2rs7279064Phe10Val1.36 (0.94-1.99)0.611.32 (0.62-2.82)0.94
IFNAR2rs2236757IVS6-50 G/A1.23 (0.85-1.78)0.631.54 (0.74-3.21)0.86
IFNGrs1861494IVS2+284 A/G0.94 (0.65-1.35)0.881.62 (0.69-3.80)0.87
IFNGR2rs1059293Ex7-134 G/A0.88 (0.58-1.33)0.791.11 (0.18-6.70)0.98
TNFrs1799964A-1031G1.23 (0.84-1.80)0.630.261.28 (0.58-2.86)0.940.16
TNFrs1800630C-863A1.39 (0.93-2.09)0.611.27 (0.52-3.06)0.94
TNFrs1800629G-308A0.75 (0.50-1.12)0.610.38 (0.16-0.91)0.34
LTArs909253IVS1+90 A/G0.76 (0.53-1.10)0.611.06 (0.48-2.34)0.98
TNFRSF10Ars2235126IVS7+218 G/A0.98 (0.68-1.41)0.940.850.78 (0.37-1.66)0.940.61
TNFRSF10Ars4871857Arg209Thr1.01 (0.66-1.53)0.960.98 (0.48-2.00)0.98
TNFRSF1Ars1800692IVS4-33 G/A0.76 (0.52-1.12)0.610.270.94 (0.36-2.40)0.980.30
TNFRSF1Ars887477IVS1-2572 C/A0.73 (0.49-1.11)0.610.56 (0.26-1.19)0.74
Anti-inflammatory cytokines and cytokine receptors
IL1RNrs419598Ala57Ala0.95 (0.66-1.37)0.890.271.19 (0.40-3.48)0.980.76
IL1RNrs454078IVS6+59 T/A0.95 (0.66-1.37)0.891.16 (0.40-3.40)0.98
IL1RNrs380092IVS6+166 T/A0.80 (0.55-1.15)0.631.05 (0.31-3.51)0.98
IL4rs2243248A-1098C1.25 (0.75-2.09)0.720.271.29 (0.58-2.83)0.940.34
IL4rs2243250G-590A1.34 (0.88-2.02)0.611.41 (0.44-4.56)0.94
IL4rs2070874Ex1-168 G/A1.21 (0.80-1.83)0.710.84 (0.39-1.80)0.94
IL4rs2243268IVS2-1443 A/C1.15 (0.76-1.74)0.751.14 (0.55-2.37)0.98
IL4Rrs2243290IVS3-9 C/A1.12 (0.74-1.69)0.830.291.23 (0.59-2.56)0.940.16
IL4Rrs2057768G-29429A1.02 (0.70-1.47)0.940.94 (0.46-1.91)0.98
IL4Rrs3024544IVS3-85 G/A1.16 (0.77-1.75)0.720.44 (0.17-1.14)0.64
IL4Rrs1805011Glu400Ala0.79 (0.50-1.23)0.631.37 (0.59-3.17)0.94
IL4Rrs1805012Cys431Arg0.84 (0.53-1.34)0.720.79 (0.32-1.92)0.94
IL4Rrs1805015Ser503Pro0.91 (0.61-1.38)0.860.97 (0.47-2.00)0.98
IL4Rrs1801275Gln576Arg0.76 (0.52-1.13)0.611.58 (0.49-5.12)0.94
IL4Rrs1805016Ser752Ala0.97 (0.50-1.89)0.941.49 (0.73-3.05)0.87
IL4Rrs8832Ex12-313 G/A1.02 (0.69-1.51)0.941.19 (0.28-5.11)0.98
IL10rs3024496Ex5+210 A/G0.64 (0.42-0.96)0.560.261.76 (0.84-3.69)0.740.13
IL10rs3024491IVS1-286 C/A0.64 (0.42-0.96)0.562.50 (1.19-5.25)0.24
IL10rs1800871G-819A1.39 (0.96-2.02)0.611.32 (0.60-2.88)0.94
IL10rs1800896A-1082G0.70 (0.46-1.05)0.611.38 (0.67-2.83)0.94
IL10rs1800890T-3575A0.81 (0.55-1.18)0.632.02 (0.96-4.25)0.48
IL13rs1881457A-1469C0.93 (0.64-1.35)0.860.351.06 (0.49-2.28)0.980.14
IL13rs1800925G-1112A0.95 (0.66-1.39)0.890.67 (0.32-1.44)0.87
IL13rs1295686IVS3-24 G/A0.87 (0.59-1.27)0.721.44 (0.33-6.39)0.94
IL13rs20541Arg130Gln0.80 (0.54-1.16)0.630.46 (0.21-1.00)0.44
TGFB1rs1800469308 bp 3′STP G/A0.98 (0.68-1.42)0.941.00 (0.49-2.03)0.99
TGFBR1rs928180IVS3-2409 A/G0.67 (0.40-1.12)0.610.260.40 (0.09-1.69)0.830.30
TGFBR1rs334358IVS8+547 C/A0.77 (0.52-1.12)0.611.47 (0.70-3.09)0.87
TGFBR1rs868Ex9+195 A/G0.75 (0.51-1.11)0.611.46 (0.69-3.08)0.87
  • Abbreviation: OR, odds ratio.

  • * Adjusted for age at diagnosis/interview, smoking history (pack-year), smoking (never/ever), years of education, family history of lung cancer, history of COPD, years since COPD diagnosis, adult aspirin use (never/ever), and BMI.

  • P values for the association between individual SNPs and NSCLC risk adjusted for multiple comparisons through the Benjamini and Hochberg false discovery rate method.

  • P values for the association between each gene (for genes with more than one SNP represented in our analyses) and NSCLC risk adjusted for multiple comparisons through the Benjamini and Hochberg false discovery rate method.